Base case
| | |
18,506
|
19,954
|
Analyses of structural changes and altering assumptions
|
Indirect costs
|
Not included
|
Included
|
Dominating
|
Dominating
|
Discount rate costs and health effects
|
3% (Sweden) and 4% (Norway)
|
0%
|
17,931
|
19,250
|
5%
|
18,893
|
20,132
|
Stopping rule
|
30% reduction in 2 cycles
|
No stopping rule
|
23,412
|
24,545
|
50% reduction in 2 cycles
|
17,666
|
19,163
|
0% reduction in 2 cycles
|
21,825
|
23,070
|
Population
|
All patients
|
≥1 prior prophylactic
|
15,160
|
16,900
|
≥3 prior prophylactics
|
15,764
|
17,532
|
Utilities
|
Estimated from COI database
|
REPOSE [56]
|
14,565
|
15,702
|
PREEMPT [18, 24]
|
15,634
|
16,804
|
IBMS
|
18,219
|
19,644
|
Time horizon
|
10 years
|
5 years
|
21,481
|
22,645
|
Analysis mirroring previous erenumab analysis
|
Norwegian (NOMA) and Swedish (TLV) erenumab analyses: 10-year time horizona, indirect costs not included, ≥3 prior prophylacticsb, stopping rule 30% reduction in 2 cycles, utilities mapped from MSQ to EQ-5Dc
|
16,625
|
18,462
|